Dr. Xingli Wang

So our first strategy is looking into bettering class

follow others but trying to make our product somewhat distinct or differentiate from existing asset and that one again is on the safe ground obviously you will say most others do the same that's true but at the same time we don't let alone of the original research original target development we do this by collaborating with

the colleges and universities and research institute in china we do now have a designated fund to do this by we call hand-in-hand working model to work with you know university professors or the researchers who have been working on the novel target yet their ability to translate

into a product is not as good as we are, but our scientific strengths are not as good as they are.

So the best way is to combine both together by sharing, you know, the knowledge, sharing profit, sharing the future together.

And you're talking about five or ten years, what we're going to see ourselves.

We're going to be

fewer product but with more blockbuster potentials we're going to be majority i mean the large proportion going to be better in class but one or two going to be the we're looking into first-in-class potentials so and also we're not going to be only in china we're going to be part of global this is our second element of strategy is globalization first is innovation second globalization

And our big boss always told us, if you're not going overseas, you're going out.

Which is the way how we drive our business towards too.

The US is a major market, Europeans and all the other countries.

And we're going to choose the highest value, best product as our stepwise approach to the market outside China.

We may be initially by collaborating as you also aware our co-development and our establishment with the US and UK biotech as well as the big companies like Teva.

And then by collaborating with them, we not only gaining the competence and knowledge of the local market, we also to getting, you know, the abilities or good product development, good assets together.

And then by then we became or become a global player.

It's also as my personal ambition by staying in China for the time being.

is to see whether my experience will help one of the Chinese companies to become a true sense of MNCs, like Takeda from Japan, which had the same journey.

My feeling is

It's a matter of time.

Obviously, Beijing is one of the MNCs, but Beijing is different.